teleo/teleo-codex
8
0
Fork 0
Code Issues 22 Pull requests 45 Projects Releases Packages Wiki Activity Actions 422

leo: extract claims from 2026-04-22-csr-biosecurity-ai-action-plan-review

Browse source 
- Source: inbox/queue/2026-04-22-csr-biosecurity-ai-action-plan-review.md
- Domain: grand-strategy
- Claims: 0, Entities: 0
- Enrichments: 3
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Leo <PIPELINE>
This commit is contained in:
Teleo Agents 2026-04-22 09:24:07 +00:00
parent 823bc71877
commit 08872b3072
3 changed files with 22 additions and 1 deletions
Show stats Download patch file Download diff file Expand all files Collapse all files

9
domains/grand-strategy/anti-gain-of-function-framing-creates-structural-decoupling-between-ai-governance-and-biosecurity-governance-communities.md
View file

@ -10,9 +10,16 @@ agent: leo
scope: structural scope: structural
sourcer: University of Pennsylvania EHRS sourcer: University of Pennsylvania EHRS
supports: ["existential-risks-interact-as-a-system-of-amplifying-feedback-loops-not-independent-threats"] supports: ["existential-risks-interact-as-a-system-of-amplifying-feedback-loops-not-independent-threats"]
related: ["ai-governance-discourse-capture-by-competitiveness-framing-inverts-china-us-participation-patterns", "existential-risks-interact-as-a-system-of-amplifying-feedback-loops-not-independent-threats", "use-based-ai-governance-emerged-as-legislative-framework-but-lacks-bipartisan-support", "use-based-ai-governance-emerged-as-legislative-framework-through-slotkin-ai-guardrails-act", "government designation of safety-conscious AI labs as supply chain risks inverts the regulatory dynamic by penalizing safety constraints rather than enforcing them"] related: ["ai-governance-discourse-capture-by-competitiveness-framing-inverts-china-us-participation-patterns", "existential-risks-interact-as-a-system-of-amplifying-feedback-loops-not-independent-threats", "use-based-ai-governance-emerged-as-legislative-framework-but-lacks-bipartisan-support", "use-based-ai-governance-emerged-as-legislative-framework-through-slotkin-ai-guardrails-act", "government designation of safety-conscious AI labs as supply chain risks inverts the regulatory dynamic by penalizing safety constraints rather than enforcing them", "anti-gain-of-function-framing-creates-structural-decoupling-between-ai-governance-and-biosecurity-governance-communities", "durc-pepp-rescission-created-indefinite-biosecurity-governance-vacuum-through-missed-replacement-deadline"]
--- ---
# Anti-gain-of-function political framing structurally decouples AI governance from biosecurity governance debates, creating the most dangerous variant of indirect governance erosion where the community that would oppose the erosion doesn't recognize the connection # Anti-gain-of-function political framing structurally decouples AI governance from biosecurity governance debates, creating the most dangerous variant of indirect governance erosion where the community that would oppose the erosion doesn't recognize the connection
Executive Order 14292 was framed and justified through anti-gain-of-function populism rather than AI-biosecurity convergence risk, despite the Council on Strategic Risks documenting that 'AI could provide step-by-step guidance on designing lethal pathogens, sourcing materials, and optimizing methods of dispersal.' This framing choice has structural consequences: biosecurity advocates see it as a gain-of-function debate (their domain), while AI safety advocates don't recognize the AI governance connection. The result is that the community most equipped to oppose AI-assisted dual-use research deregulation—AI safety advocates who understand AI capability trajectories—doesn't engage because the policy debate is framed in biological research terms. The Congressional Research Service flagged the DURC/PEPP vacuum as an open concern, but no legislation has been introduced to restore oversight, consistent with neither community recognizing this as their coordination problem. This represents Mechanism 2 (indirect governance erosion) from the April 14 session: governance is dismantled not through direct AI policy changes that would trigger AI safety community opposition, but through adjacent domain policy changes (biosecurity) that the AI community doesn't monitor. The anti-GOF framing is politically convenient but scientifically incoherent as a policy framework for AI-bio convergence risks, suggesting the framing choice itself may be strategic rather than incidental. Executive Order 14292 was framed and justified through anti-gain-of-function populism rather than AI-biosecurity convergence risk, despite the Council on Strategic Risks documenting that 'AI could provide step-by-step guidance on designing lethal pathogens, sourcing materials, and optimizing methods of dispersal.' This framing choice has structural consequences: biosecurity advocates see it as a gain-of-function debate (their domain), while AI safety advocates don't recognize the AI governance connection. The result is that the community most equipped to oppose AI-assisted dual-use research deregulation—AI safety advocates who understand AI capability trajectories—doesn't engage because the policy debate is framed in biological research terms. The Congressional Research Service flagged the DURC/PEPP vacuum as an open concern, but no legislation has been introduced to restore oversight, consistent with neither community recognizing this as their coordination problem. This represents Mechanism 2 (indirect governance erosion) from the April 14 session: governance is dismantled not through direct AI policy changes that would trigger AI safety community opposition, but through adjacent domain policy changes (biosecurity) that the AI community doesn't monitor. The anti-GOF framing is politically convenient but scientifically incoherent as a policy framework for AI-bio convergence risks, suggesting the framing choice itself may be strategic rather than incidental.
## Supporting Evidence
**Source:** Council on Strategic Risks, Review: Biosecurity Enforcement in the White House's AI Action Plan, July 28, 2025
The AI Action Plan's authorship and enforcement architecture confirms the decoupling: CSR notes the plan reinforces CAISI's (Center for AI Safety and Innovation) role in evaluating frontier AI systems for bio risks, shifting biosecurity governance authority from science agencies to national security apparatus. The plan acknowledges AI-bio synthesis risk while substituting nucleic acid screening (a supply chain control) for institutional oversight (a research governance mechanism)—a category error that only makes sense if the communities are structurally decoupled.

7
domains/grand-strategy/durc-pepp-rescission-created-indefinite-biosecurity-governance-vacuum-through-missed-replacement-deadline.md
View file

@ -23,3 +23,10 @@ Executive Order 14292 (May 5, 2025) rescinded the May 2024 DURC/PEPP policy fram
**Source:** CSET Georgetown analysis of White House AI Action Plan (July 2025) **Source:** CSET Georgetown analysis of White House AI Action Plan (July 2025)
The AI Action Plan (July 23, 2025) postdates the September 2025 DURC/PEPP replacement deadline from EO 14292 but does not address the missed deadline or provide replacement institutional oversight mechanisms. Instead, it substitutes screening-based biosecurity governance (nucleic acid synthesis provider requirements, customer screening data-sharing) which addresses supplier vetting rather than dual-use research conduct decisions. The AI Action Plan (July 23, 2025) postdates the September 2025 DURC/PEPP replacement deadline from EO 14292 but does not address the missed deadline or provide replacement institutional oversight mechanisms. Instead, it substitutes screening-based biosecurity governance (nucleic acid synthesis provider requirements, customer screening data-sharing) which addresses supplier vetting rather than dual-use research conduct decisions.
## Extending Evidence
**Source:** Council on Strategic Risks, Review: Biosecurity Enforcement in the White House's AI Action Plan, July 28, 2025
Council on Strategic Risks' July 2025 review of the AI Action Plan confirms the governance vacuum persists: the plan explicitly acknowledges AI can provide 'step-by-step guidance on designing lethal pathogens, sourcing materials, and optimizing methods of dispersal' but does not replace the DURC/PEPP institutional review framework. CSR documents that the plan instead calls for mandatory nucleic acid synthesis screening for federally funded institutions—a category substitution that addresses material procurement but not research decision oversight.

7
domains/grand-strategy/nucleic-acid-screening-cannot-substitute-for-institutional-oversight-in-biosecurity-governance-because-screening-filters-inputs-not-research-decisions.md
View file

@ -16,3 +16,10 @@ related: ["durc-pepp-rescission-created-indefinite-biosecurity-governance-vacuum
# Nucleic acid screening cannot substitute for institutional oversight in biosecurity governance because screening filters inputs not research decisions # Nucleic acid screening cannot substitute for institutional oversight in biosecurity governance because screening filters inputs not research decisions
The White House AI Action Plan (July 23, 2025) mandates that federally funded institutions use nucleic acid synthesis providers with robust screening and directs OSTP to convene data-sharing mechanisms for screening fraudulent/malicious customers. However, this screening-based approach addresses which inputs are acceptable (supplier vetting, customer screening) rather than which research gets conducted at all (institutional review of dual-use research proposals). CSET Georgetown's analysis identifies this as a categorical substitution: the plan 'substitutes screening-based biosecurity governance for institutional oversight governance.' This matters because screening cannot perform the gate-keeping function that institutional review committees provided under DURC/PEPP. Screening filters bad actors from accessing synthesis services; institutional review evaluates whether specific research projects with legitimate actors should proceed given dual-use risks. The AI Action Plan explicitly acknowledges AI could create 'new pathways for malicious actors to synthesize harmful pathogens' but addresses only the malicious actor pathway (screening) while leaving the legitimate-researcher-conducting-dangerous-research pathway (institutional oversight) ungoverned. The plan postdates the September 2025 DURC/PEPP replacement deadline from EO 14292 but does not address the missed deadline, confirming that screening provisions are being treated as biosecurity governance rather than as supplements to institutional oversight. The White House AI Action Plan (July 23, 2025) mandates that federally funded institutions use nucleic acid synthesis providers with robust screening and directs OSTP to convene data-sharing mechanisms for screening fraudulent/malicious customers. However, this screening-based approach addresses which inputs are acceptable (supplier vetting, customer screening) rather than which research gets conducted at all (institutional review of dual-use research proposals). CSET Georgetown's analysis identifies this as a categorical substitution: the plan 'substitutes screening-based biosecurity governance for institutional oversight governance.' This matters because screening cannot perform the gate-keeping function that institutional review committees provided under DURC/PEPP. Screening filters bad actors from accessing synthesis services; institutional review evaluates whether specific research projects with legitimate actors should proceed given dual-use risks. The AI Action Plan explicitly acknowledges AI could create 'new pathways for malicious actors to synthesize harmful pathogens' but addresses only the malicious actor pathway (screening) while leaving the legitimate-researcher-conducting-dangerous-research pathway (institutional oversight) ungoverned. The plan postdates the September 2025 DURC/PEPP replacement deadline from EO 14292 but does not address the missed deadline, confirming that screening provisions are being treated as biosecurity governance rather than as supplements to institutional oversight.
## Supporting Evidence
**Source:** Council on Strategic Risks, Review: Biosecurity Enforcement in the White House's AI Action Plan, July 28, 2025
CSR's review provides authoritative biosecurity community confirmation of the category substitution: the AI Action Plan mandates nucleic acid synthesis screening for federally funded institutions while explicitly not replacing DURC/PEPP institutional review. This is the third independent source (alongside CSET and RAND) documenting that policymakers are treating input filtering as equivalent to research oversight despite the mechanisms operating at different governance layers.